BPH Global Finalises Men’s Health Supplement Formula, Moves Toward Efficacy Testing

Stemcell United Ltd. ( (AU:BP8) ) has issued an announcement.

BPH Global has completed the final formulation of its proprietary seaweed-based men’s health supplement under Project Giddy-Up, locking in all ingredients and their proportions to move from development into validation. The company is maintaining its strategy to secure listing of the product as a TGA-listed complementary medicine on the Australian Register of Therapeutic Goods.

The company has received a draft services agreement from Temasek Innovation Holdings in Singapore for a two-stage, cell-based efficacy testing program and is now reviewing the terms ahead of planned execution. Next steps include finalising the agreement, coordinating with Temasek on the R&D work program, and progressing efficacy testing, which will be critical to underpin regulatory submissions and future market positioning.

The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.

More about Stemcell United Ltd.

BPH Global Ltd is an ASX-listed company developing a proprietary seaweed-based men’s health supplement under Project Giddy-Up. The product is being advanced as a complementary medicine aimed at registration on the Australian Register of Therapeutic Goods, targeting the men’s health segment with a focus on scientifically validated, seaweed-derived formulations.

Current Market Cap: A$4.71M

For an in-depth examination of BP8 stock, go to TipRanks’ Overview page.